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Murine leukemia viruses (MLVs) can be lymphomagenic and bone pathogenic. In this work, the possible roles of two distinct proviral
enhancer nuclear factor 1 (NF1) binding sites in osteopetrosis and tumor induction by B-lymphomagenic Akv1-99 MLV were investigated.
Akv1-99 and mutants either with NF1 site 1, NF1 site 2 or both sites disrupted induced tumors (plasma cell proliferations by histopathology)
with remarkably similar incidence and mean latency in inbred NMRI mice. Clonal immunoglobulin gene rearrangement detection, by
Southern analysis, confirmed approximately half of the tumors induced by each virus to be plasmacytomas while the remaining lacked
detectable clonally rearranged Ig genes and were considered polyclonal; a demonstration that enhancer NF1 sites are dispensable for
plasmacytoma induction by Akv1-99. In contrast, X-ray analysis revealed significant differences in osteopetrosis induction by the four
viruses strongly indicating that NF1 site 2 is critical for viral bone pathogenicity, whereas NF1 site 1 is neutral or moderately inhibitory. In
conclusion, enhancer NF1 sites are major determinants of osteopetrosis induction by Akv1-99 without significant influence on viral
oncogenicity.
D 2005 Elsevier Inc. All rights reserved.
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Murine leukemia viruses (MLVs) are simple retroviruses,
which can induce hematopoietic malignancies in mice. In
addition, some MLVs hold a considerable potential for
induction of bone lesions such as osteomas (benign bone
tumors) (Luz et al., 1991) and osteopetrosis, a generalized
disorder of the skeleton characterized by a significantly
augmented bone mass, which in severe cases may com-
pletely fill the bone marrow cavity with osteoid, yet
maintain the overall shape of the skeleton (Ethelberg et0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: fsp@mb.au.dk (F.S. Pedersen).al., 1999; Murray et al., 1991; Schmidt et al., 1999). The
condition seems to evolve primarily via osteoblast defects
and secondarily via osteoclasts (Schmidt et al., 1999) and
may therefore also be termed osteosclerosis (Whyte, 1996).
MLV-induced osteopetrosis has always been found associ-
ated with tumor development (Ethelberg et al., 1999;
Gimbel et al., 1996; Lovmand et al., 1998; Murray et al.,
1991; Schmidt et al., 1984), but it is unclear if there is a
coupling between the disease processes (Schmidt et al.,
1999). In man, localized bone lesions (mostly lytic, rarely
osteosclerotic) are common clinical features of multiple
myeloma and adult T-cell leukemia and seem to develop in
response to tumor cell-mediated effects in the bone marrow
microenvironment (Mundy, 1997; Roodman, 1997).
Important genetic determinants of MLV lymphomage-
nicity have been mapped to the proviral U3 enhancer05) 234–244
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DesGroseillers and Jolicoeur, 1984; Lenz et al., 1984),
and in some cases to individual transcription factor binding
sites (Hallberg and Grundstro¨m, 1988; Nieves et al., 1997;
Speck et al., 1990); however, little is known about genetic
determinants of MLV-induced bone disease. By using
chimeras of highly bone pathogenic RFB MLV and T-
lymphomagenic SL3-3 MLV non-LTR sequences were
identified as major determinants of osteoma induction
(astergaard et al., 1997). Also, Runx (core/AML1) and
nuclear factor 1 (NF1) binding sites in the enhancer of SL3-
3 were found to be important for viral osteopetrosis
induction (Ethelberg et al., 1999) with only the former
playing a significant role also in lymphomagenesis (Ethel-
berg et al., 1997a; Hallberg et al., 1991).
Akv1-99 is an ecotropic MLV derived from endogenous
Akv MLVof the AKR mouse by deletion of one copy of the
99-bp transcriptional enhancer in the proviral LTR (Lov-
mand et al., 1998). Both viruses induce B-cell lymphomas
with high incidence and 12 months mean latency in random-
bred NMRI mice (Lovmand et al., 1998). Akv is also
significantly bone pathogenic (Gimbel et al., 1996; Luz et
al., 1991; Murray et al., 1991; Schmidt et al., 1995),
whereas reports of bone disease induction by Akv1-99 are
rare (Lovmand et al., 1998) with no previous records of
osteopetrosis. The 99-bp enhancer of Akv1-99 contains two
distinct NF1 motifs, termed NF1 site 1 and 2, respectively.
The NF1 site 2 sequence is a part of the conserved MLV
enhancer framework (Golemis et al., 1990) and identical to
the NF1 site present in three copies in the enhancer of SL3-3
MLV (Ethelberg et al., 1997a, 1997b, 1999; Hallberg et al.,
1991; Nieves et al., 1997). NF1 factors bind to DNA as
homo- or heterodimers, and numerous complexes with
regulatory abilities ranging from activation to repression of
transcription can be formed from several splice variants of
the four NF1 family genes (Chaudhry et al., 1998; Gao and
Kunos, 1998; Gronostajski, 2000; Kruse and Sippel, 1994;
Mermod et al., 1989). NF1 site 1 is a stronger in vitro
binding sequence than NF1 site 2 for a protein complex
compatible with NF1 (Olsen et al., 1990), but the molecular
interactions between NF1 motifs in Akv1-99 and NF1
proteins remain to be examined in detail with a possibility
that these sites are recognized by other factors in vivo.
In this study, three different enhancer mutants of Akv1-
99 were generated to investigate the function of NF1 site 1
and NF1 site 2 in viral lymphoma and osteopetrosis
induction. The study was based on our previous identifica-
tion of enhancer NF1 sites as major determinants of
osteopetrosis but not T-cell lymphoma induction by closely
related SL3-3 MLV (Ethelberg et al., 1999). We found that
the two NF1 sites regulate Akv1-99 enhancer activity in a
highly cell type-dependent manner, ranging from strong
stimulation to moderate repression. Cell type-specific differ-
ences were also prominent at the level of viral pathogenicity,
since Akv1-99 and three NF1 site mutant viruses induced
plasmacytomas with similar incidence and latency, butshowed markedly different osteopetrosis induction capaci-
ties. Interestingly, NF1 site 2 (identical to the SL3-3 NF1
site sequence) was critical for osteopetrosis induction, while
NF1 site 1 was neutral or moderately inhibitory. Thus, the
separate roles of enhancer NF1 sites in tumor and
osteopetrosis induction are similar for SL3-3 and Akv1-99
despite the distinct cell type specificities of oncogenic
transformation.Results
NF1 sites regulate Akv1-99 enhancer activity in a cell
type-specific manner
To investigate the role of NF1 binding sites in transcrip-
tional regulation of Akv1-99, enhancer reporter constructs
with wild-type or mutated NF1 motifs were tested in
transient expression assays in MPC11 B-cells, NALM6
pre-B-cells, L691 T-cells, MC 3T3 osteoblast-like cells and
KM1/K3 osteoblast progenitor cells. NIH 3T3 fibroblasts
were included as non-hematopoietic, non-bone mesenchy-
mal cells known to contain NF1 site binding proteins in
abundance (Goyal et al., 1990). The reporter plasmid p1-
99(wt)-cat (Lovmand et al., 1990) harbors a complete
Akv1-99 LTR to drive expression of a chloramphenicol
acetyltransferase (CAT) reporter gene. The mutated con-
structs p1-99(m1)-cat, p1-99(m2)-cat and p1-99(dmNF1)-
cat have substitutions in either NF1 site 1 or 2, or in both
NF1 sites simultaneously (Fig. 1). Both half sites of the
palindromic NF1 motifs were mutated to completely abolish
in vitro binding of a protein complex with NF1 properties
(Lovmand, 1996; Olsen et al., 1990). In the previous study,
SL3-3 NF1 site mutants had a single 3-bp mutation in the
upstream half site (Ethelberg et al., 1999).
Transient expression results are shown in Table 1 with
average CAT activities of the different experiments given
relative to the mean CAT activity measured for a similar
expression vector, pAkv6cat (Lovmand et al., 1990), with
two copies of the wild-type 99-bp enhancer sequence. The
two NF1 sites were functionally indistinguishable in this
assay, since p1-99(m1)-cat and p1-99(m2)-cat gave similar
results in each of the six cell lines tested. In all cases,
the effect of mutating two rather than one NF1 motif
was largely additive. Disrupting both NF1 sites reduced
CAT expression 10-fold in NIH 3T3 fibroblasts, consistent
with the high levels of NF1 binding activity in this cell
line (Goyal et al., 1990). The clearly most dramatic effects
of NF1 site mutations, however, were seen in MC 3T3
and KM1/K3 osteoblastic cells in which mutation of
both NF1 sites lowered Akv1-99 enhancer activity approxi-
mately 30-fold. These results suggest that enhancer
NF1 motifs are of major importance for expression of
Akv1-99 in osteoblasts and osteoblast precursor cells and
may influence the osteopetrosis induction potential of the
virus.
Fig. 1. LTR and enhancer structures of Akv and Akv1-99. The 99-bp tandemly duplicated transcriptional enhancer of Akv is present in only one copy in the U3
region of Akv1-99. The 99-bp enhancer sequence contains two distinct nuclear factor 1 (NF1) transcription factor binding sites, NF1 site 1 and 2, respectively,
besides an Ets site, a Runx site, an E-box site and a glucocorticoid response element (GRE). NF1 site 2 is also referred to as the enhancer framework NF1 site.
Point mutations introduced into the NF1 sites of Akv1-99-based CAT expression plasmids or provirus constructs are shown at the bottom. The primer pair used
for PCR amplification of proviral U3 regions is shown at the top. 5V UTR, 5V untranslated region.
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plasmacytoma B-cells and 4-fold in NALM6 pre-B-cells
when both NF1 sites were mutated. Although this indicates
that the NF1 sites stimulate Akv1-99 enhancer activity in
the lymphoid target cells of Akv1-99, and thereby may
contribute to viral oncogenicity, we note that the impact of
NF1 site mutations was much less pronounced in the
hematopoietic cell lines than in the osteoblastic cell lines
used here. Finally, the transient assays showed that NF1
sites are weak negative regulators of Akv1-99 enhancer
activity in L691 T-cells, as evident only when two sites were
mutated simultaneously.
Together with earlier work (Ethelberg et al., 1997a, 1999;
Olsen et al., 1990), this study revealed similar regulatoryTable 1
Results of transient expression experiments
Expression vector Relative CAT activity (SD)a
MPC 11 NALM6 L69
pAkv6cat 100 100 100
p1-99(wt)-cat 101 (22) 41 (11) 193
p1-99(m1)-cat 24 (6) 23 (9) 150
p1-99(m2)-cat 28 (11) 23 (6) 205
p1-99(dmNF1)-cat 16 (11) 10 (5) 318
a Transient transfection assays with CAT reporter constructs. The average CAT act
100. Standard deviations of 3–11 independent transfections are given in parenthe
b We note that the quantification of Akv1-99(m1) LTR-driven CAT expression inroles for NF1 sites in viral transcriptional control in the five
different cell lines, MPC11, L691, NIH 3T3, MC 3T3 and
KM1/K3, regardless of their location being in the enhancer
context of B-lymphomagenic Akv1-99 or T-lymphomagenic
SL3-3. In both cases, viral enhancer activity was up-
regulated via intact NF1 binding sites in the B-lymphoid
and osteoblastic cell lines, but down-regulated in L691 T-
cells. Hence, the varying CAT activities measured for
pAkv6cat versus p1-99(wt)-cat in NALM6, L691, NIH
3T3, MC 3T3 and KM1/K3 cells (Table 1) may at least in
part be explained by different numbers of NF1 motifs in the
U3 enhancers. No effect of repeat number variation was
seen in MPC11 cells, probably due to involvement of other
factors.1 NIH 3T3 MC 3T3 KM1/K3
100 100 100
(24) 52 (20) 65 (18) 26 (9)
(31) 12 (5)b 9 (4) 2 (0.6)
(79) 15 (6) 5 (2) 3 (2)
(50) 5 (3) 2 (0.8) 1 (0.8)
ivities are normalized to the activity of Akv6cat, which was arbitrarily set to
ses. All transfections were performed in duplicate.
NIH 3T3 cells repeats and confirms earlier work (Olsen et al., 1990).
Table 2








Akv1-99 19/20 (95%) 186 (28) 12/20 (60%)
Akv1-99(m1) 16/17 (94%) 187 (19) 13/17 (76%)
Akv1-99(m2) 44/44 (100%) 182 (28) 0/44 (0%)
Akv1-99(dmNF1) 18/20 (90%) 187 (25) 3/20 (15%)c
Mockd 1/21 (4.8%) NDe 0/21 (0%)
a No. of mice with tumors/no. of injected mice. Within a 1-year observation
period.
b As determined by X-ray analysis.
c Significantly different from Akv1-99 ( P b 0.05), Akv1-99(m1) ( P b
0.005) and p1-99(m2) ( P b 0.05) (Fischer’s exact test, two tailed).
d The mock-injected controls (data from Ethelberg et al., 1999) belonged to
the same colony of inbred NMRI mice as the virus-injected mice, and were
kept in the same facility.
e ND, not determined.
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Akv1-99
To investigate the role of enhancer NF1 sites for viral
oncogenicity, infectious Akv1-99 virus particles with
mutations in NF1 site 1, NF1 site 2 or both NF1 sites were
injected into newborn inbred NMRI mice together with
wild-type Akv1-99. Akv1-99 and the three mutant viruses
induced tumors with remarkably similar incidence and mean
latency periods of 6 months (Fig. 2; Table 2).
The morphological changes observed in the lymphoid
organs of mice infected with any of the four viruses were
very similar. Cervical and mesenteric lymph nodes were
significantly enlarged and revealed a complete effacement
of the normal architecture by a diffuse and sometimes
vaguely nodular proliferation (Fig. 3A). At higher magni-
fication, most of the nodules were composed of a
monotonous infiltration of medium-sized plasma cells with
abundant cytoplasm, eccentric nuclei, and marginated
chromatin (Fig. 3B). Hyperplastic germinal centers were
identified in some areas (Fig. 3C). The germinal centers had
ill-defined borders, abundant tingible-body macrophages
and lacked well-formed mantle and marginal zones (Fig.
3C). In addition to the lymph nodes, the spleen was also
infiltrated with expansion of the white pulp (Fig. 3D).
Extramedullary hematopoiesis in the spleen was always
present. Histologically, a diagnosis of plasma cell prolifer-
ation (consistent with plasmacytoma, i.e. plasma cell lym-
phoma) was made in all cases.
Macroscopically, an enlarged thymus was identified in
only three cases; however, in many instances the medulla
was infiltrated by the plasma cell proliferation (Fig. 3E). In
some cases, the liver revealed an infiltrate in the portal tracts
(Fig. 3F). Immunostaining for CD79a confirmed the B-cell
nature of the residual follicles (Figs. 3G–H) and highlighted
the typical plasma cell morphology of the infiltrate.
Intermingled small reactive T-lymphocytes were positive
for CD3 (not shown). TdT was negative in all cases (notFig. 2. Tumor induction in inbred NMRI mice injected with Akv1-99 or
NF1 site-mutated viruses. The cumulative mortality is given as a function of
the latency time.shown), excluding the possibility of a pre-B lymphoblastic
lymphoma.
For further characterization, Southern blotting analysis of
genomic tumor DNA was performed with hybridization
probes derived from the immunoglobulin kappa light chain
(Ign), immunoglobulin heavy chain (IgH) and T-cell
receptor h (TCRh) loci. The molecular analyses did not
reveal any significant differences between tumors induced
by Akv1-99 and the three NF1 site mutants (Table 3; Fig. 4).
Clonal Ign and IgH gene rearrangements were detected in
approximately one half of the mice infected with either of
the four viruses, consistent with plasmacytoma. In five
mice, weak TCRh gene rearrangements were detected with
the J2 but not the J1 probe; however, these tumors also had
mono- or oligoclonal Ign and IgH gene rearrangements (Fig.
4A, no. 3, 9–10; Fig. 4C, no. 8; and data not shown),
altogether in support of a B-cell rather than a T-cell tumor
phenotype. Unexpectedly, in a few tumors of each series,
clonal DNA rearrangements were detected in only one of
the analyzed Ig loci (Fig. 4D, tumor 3, and data not shown).
There was no morphological evidence of a pre-B cell
lymphoma phenotype in the tumors showing rearrangement
of IgH but not Ign, and it is possible that at least some of
them have the lambda rather than the kappa light chain gene
clonally rearranged.
In the remaining one half of the mice injected with each
virus, no clonal rearrangements were detected in the three
genes investigated by Southern analysis (Table 3; Fig. 4).
Following the recommendations of the 2002 Bethesda
mouse lymphoma classification system (Morse et al.,
2002), and in the absence of morphological evidence of a
null lymphoma phenotype, these cases were considered
polyclonal. Although we cannot formally prove that the
polyclonal plasma cell proliferations are malignant B-cell
tumors, it is notable that histologically these cases could not
be distinguished from the plasmacytomas with detectable Ig
rearrangements and in all cases developed with similar mean
latency.
Fig. 3. Histological appearance of tumors induced by wild-type and NF1 site-mutated Akv1-99 viruses. (A) Mesenteric lymph node in a mouse infected with
wild-type Akv1-99 MLV. The normal architecture of the lymph node is effaced by a nodular proliferation of medium-sized plasma cells (hematoxylin and eosin).
(B) Mesenteric lymph node in a mouse infected with Akv1-99(m1). The lymph node is diffusely infiltrated by a monotonous proliferation of medium-sized
plasma cells with abundant cytoplasm, eccentric nuclei and marginated chromatin. Occasionally a small nucleolus is identified (hematoxylin and eosin). (C)
Mesenteric lymph node in a mouse infected with Akv1-99(m1). The lymph node is diffusely infiltrated by plasma cells. There is partial preservation of the
lymph node architecture with ill-defined germinal centers (GC) that show a starry sky pattern and lack mantle zones (hematoxylin and eosin). (D) Spleen in a
mouse infected with Akv1-99(m1). The white pulp of the spleen is expanded by a vaguely nodular infiltrate composed of medium-sized plasma cells. Rare
residual germinal centers are identified. Note the intense erythropoiesis in the subcapsular area (hematoxylin and eosin). (E) Thymus in a mouse infected with
Akv1-99(dmNF1). The medulla of the thymus is expanded by a proliferation of plasma cells. Note that the cortical area is compressed (hematoxylin and eosin).
(F) Liver in a mouse infected with Akv1-99(m1). The liver shows a marked infiltrate in the portal tracts surrounding blood vessels and bile ducts (hematoxylin
and eosin). (G) Mesenteric lymph node stained with anti-CD79a. The B-cells in the germinal center (GC) show a specific membranous staining. The strong
staining of cytoplasmic immunoglobulin by the secondary antibody highlights the typical plasma cell morphology surrounding the GC (immunohistochemistry).
(H) Higher magnification of a nodule composed almost exclusively of plasma cells (immunohistochemistry).
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dispensable for plasmacytoma induction by Akv1-99. Hence,
the significant effects on viral enhancer activity measured in
two B-lymphoid cell lines, including a murine plasmacytoma
cell line (MPC11), after mutating one or both NF1 site(s)(Table 1) were not manifested at the level of viral tumor-
igenicity. We note that the lymphoma latency period of
Akv1-99 was significantly shorter in inbred NMRI mice, as
shown here, than in random-bred NMRI mice, as reported
earlier (Lovmand et al., 1998). This may mask small
Table 3
Molecular tumor characterization
Virus No. of mice DNA rearrangementsa Lymphoma
with tumor
development
Ign IgH TCRh-J1 TCRh-J2 incidence
b
Akv1-99 19 9/17 11/16 0/10 3/10 11/18
Akv1-99(m1) 16 5/11 8/14 0/10 0/12 9/15
Akv1-99(m2) 44 9/16 8/16 0/16 2/16 9/16
Akv1-99(dm) 18 9/18 4/11 0/10 0/14 11/18
a As determined by Southern blotting analysis of genomic tumor DNAwith Ig- and TCRh-specific hybridization probes (Ign, IgH, TCRh-J1 and -J2). No. of
tumors with clonal rearrangements/no. of tumors investigated.
b Incidence of malignant lymphoma with clonal Ig gene rearrangements. No. of mice with clonal Ig gene rearangements detected/no. of mice analyzed. In a
few cases, data was available for only one of the Ig chain genes.
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viruses.
Proviral enhancer sequences were conserved in tumor DNA
Structural alterations or secondary mutations in the
proviral enhancer region may arise in vivo and influence
viral pathogenicity. To determine if the viral enhancers were
genetically stable during lymphoma induction, proviral U3
regions were PCR amplified from genomic tumor DNAs of
69 mice, equally representing the four different viruses, by
using a primer in the 5V end of the U3 and a primer located
ca. 60-bp downstream of the 99-bp enhancer element (Fig.
1). In all cases, only a single band of the size (277-bp)
expected from the U3 structures of the input viruses was
seen (data not shown), ruling out that major fluctuations in
enhancer repeat copy numbers had occurred during viral
tumor induction. Bulk sequencing of the PCR products
(from nucleotide positions 42 to 260 of the viral LTRs)
showed that the introduced NF1 site point mutations were
always maintained, and that the wild-type enhancer
sequence also had not changed. Second-site mutations
were not discovered. This pronounced in vivo stability
correlates well with the limited role of NF1 sites for Akv1-
99 lymphomagenicity, most probably resulting in a mini-
mum selection force against the mutated enhancers during
tumorigenesis.
NF1 site 2 is a major determinant of osteopetrosis induction
by Akv1-99
The bone pathogenic properties of wild-type or NF1 site-
mutated Akv1-99 were evaluated by X-ray analysis of all
deceased mice using the increase in cancellous bone mass,
marked trabecular thickening, and loss of marrow cavity as
characteristics of osteopetrosis (Ethelberg et al., 1999; Luz et
al., 1991; Murray et al., 1991; Schmidt et al., 1999). This is a
fast and reliable method for detection of MLV-induced
osteopetrosis and, as previously shown in details, is well
correlated with results obtained by laborious histological
analyses, although the sensitivity of the latter is higher
(Ethelberg et al., 1999; Murray et al., 1991; Schmidt et al.,
1999).By X-ray analysis, we found that the osteopetrosis
induction potentials of the four viruses differed markedly.
Akv1-99 induced osteopetrosis in 60% of the mice (Table
2). Mutation only of NF1 site 1 had no significant effect on
viral bone pathogenicity, but radiologically detectable
osteopetrosis induction was completely abolished by muta-
tion only of NF1 site 2 (Table 2), strongly indicating a
pivotal role of NF1 site 2 but not NF1 site 1 for induction of
the skeletal lesion. The double mutant induced osteopetrosis
in 15% of the mice (Table 2), showing that NF1 site 2 is not
strictly required for osteopetrosis induction by Akv1-99. It
also indicates that NF1 site 1 at least to some extent may
inhibit viral bone pathogenicity, although this was not
statistically significant by comparison of Akv1-99 and
Akv1-99(m1).
The transient enhancer activities of wild-type and NF1
site-mutated Akv1-99 measured in MC 3T3 and KM1/K3
cells (Table 1) did not correlate well with the osteopetro-
genic potencies of the corresponding viruses in inbred
NMRI mice, although the two weakly bone pathogenic
mutants both exhibited severely reduced enhancer strengths
in the osteoblastic cell lines. This pattern is similar to our
earlier findings for NF1 site mutants of SL3-3 (Ethelberg et
al., 1999).
The present study is the first to identify an osteopetrosis
induction potential by Akv1-99, which did not induce
radiologically detectable osteopetrosis in random-bred
NMRI mice, although osteomas developed with low
incidence (Lovmand et al., 1998). None of the inbred
NMRI mice infected with Akv1-99, Akv1-99(m1) or Akv1-
99(dmNF1) had osteomas at the time of lymphoma
development. This was not investigated for Akv1-99(m2).
It is possible that the shorter tumor latency in inbred NMRI
mice does not allow sufficient time for osteoma develop-
ment, but the differences may rely also on other mouse
strain specific factors.Discussion
In this study, we have identified enhancer NF1 sites as
major genetic determinants of osteopetrosis but not plasma-
cytoma induction by Akv1-99 MLV. NF1 site 1 was neutral
Fig. 4. Tumor characterization by Southern hybridizations. Genomic DNA from tumors induced by Akv1-99 (A), Akv1-99(m1) (B), Akv1-99(m2) (C) and
Akv1-99(dmNF1) (D) was cleaved by HindIII and hybridized with the Ign, TCRh-J1 or TCRh-J2 probes, or cut with EcoRI for hybridization with the IgH
probe. Tumor numbers are given above each lane. (C) gDNA from a non-injected control mouse. In some cases, more than one tumor tissue was analyzed from
the same mouse as indicated by one-letter abbreviations (c, cervical lymph node; m, mesenteric lymph node; p, para-aortic lymph node; s, spleen; t, thymus).
Size markers (kb) are shown to the left of each blot. Black bars indicate the positions of genomic germline fragments. Some weak rearranged bands are
highlighted by arrows.
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development, whereas NF1 site 2 was critical though not
absolutely essential. Hence, the divergent functions of the
enhancer framework NF1 site sequence in viral tumor
versus osteopetrosis induction are similar for Akv1-99 MLV,
as shown here, and SL3-3 MLV, as reported earlier
(Ethelberg et al., 1999), despite distinct cell type specific-
ities of oncogenic transformation and differences between
the exact point mutations used. The limited role of NF1 sitesin lymphoma induction by Akv1-99 and SL3-3 may be a
characteristic trait of Akv family viruses and contrasts a
significant attenuation of T-lymphomagenesis by MoMLV
upon mutation of an enhancer NF1 site present in two
copies (Speck et al., 1990).
Reports of lymphoma induction by exogenous Akv or
Akv1-99 are relatively rare (Lovmand et al., 1998; Speth et
al., 1995), but several studies have pointed to a role of
activated endogenous Akv in spontaneous models, includ-
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mice (Hartley et al., 2000) and some AKXD strains (Gilbert
et al., 1993; Mucenski et al., 1986, 1987). Expression of an
endogenous ecotropic MLV, which may be identical to Akv
(Jenkins et al., 1982; Yamada et al., 1994), is critical for the
occurrence of pre-B-cell lymphomas in SL/Kh mice
(Yamada et al., 1994). The ecotropic emv-1 locus, harboring
a U3 sequence that differs from Akv1-99 only at a single
position upstream of the enhancer (Lawrenz-Smith et al.,
1994), may contribute to B-cell lymphomagenesis in CWD
and SEA/GnJ mice (Angel and Bedigian, 1984; Mucenski et
al., 1988), but seems not to be important for pristane-
induced plasmacytomas in BALB/c mice (Potter and Wax,
1983; Potter et al., 1984).
Interestingly, the tumors induced by Akv1-99 and the
three NF1 site mutants in inbred NMRI mice were
plasmacytomas, while Akv1-99 induced only less differ-
entiated types of B-cell malignancies (mostly B-cell
lymphoblastic lymphoma) in random-bred NMRI mice
(Lovmand, 1996; and unpublished results). We note that
in inbred NMRI mice several independent tumors displayed
rearranged fragments of similar size when analyzed by
Southern blotting with the Ig kappa and Ig heavy chain
probes (Fig. 4, and data not shown), a pattern not observed
in random-bred NMRI mice (Lovmand et al., 1998). Such
fragments were never seen in samples from negative
controls of the same inbred NMRI colony and are therefore
unlikely to represent odd cases of incompletely digested
DNA samples.
Although comigration of fragments does not prove
identity, it raises the possibility that Ig rearrangements are
restricted in the tumors, further indicative of antigenic
stimulation playing a key role in tumorigenesis. Repetitive
usage of certain Ig gene segments occurs in spontaneous
CD5+ (B1) B-cell lymphomas in old mice of some strains
(Rosner et al., 1993; Stall et al., 1988) and in young
autoimmune NZB mice (Stall et al., 1988; Tarlinton et al.,
1988). B1-cells in the peritoneal cavity (Stall et al., 1988)
may be easily accessible for MLV infection upon ip
inoculation, as performed here, and have also been
suggested as possible precursors of pristane-induced plas-
macytomas in the BALB/c mouse model (Potter and
Wiener, 1992), which seems to require antigenic stimulation
(Byrd et al., 1991). In man, restricted usage of Ig variable
region sequences has been found in plasmacytomas
associated with hepatitis C virus (HCV) infection (Gaspar-
otto et al., 2002), and despite some controversy, there is
increasing evidence for a role of HCV antigen-driven clonal
B-cell expansion in at least some B-cell lymphoproliferative
disorders (Weng and Levy, 2003).
We speculate that in the current model, MLV-induced
plasmacytomas develop through a sequential process
involving a benign restricted lymphoid expansion (hyper-
plasia), followed by an oligoclonal phase, which ultimately
may lead to a monoclonal neoplastic proliferation (frank
plasmacytoma). Antigenic stimulation from opportunisticinfections might play a role during one or more of these
steps, still only one of the mock-injected mice presented
with signs of illness within the 1-year observation period,
proving the essential role of MLV infection for tumori-
genesis. An oligoclonal expansion is detectable by Southern
analysis only if the proliferating population has reached a
sufficient size and may explain the absence of clonal Ig gene
rearrangements in half of the virus-injected mice. In many,
but not all, positive cases the rearranged Ig bands were
relatively weak (Fig. 4 and data not shown), which together
with the highly similar histological observations for all
investigated mice is consistent with the model of gradual
progression from polyclonal plasma cell proliferation
toward mono- or oligoclonal plasmacytoma. The most
common human plasma cell malignancy, multiple myeloma,
is usually if not always preceded by a benign plasma cell
proliferation (monoclonal gammopathy of undetermined
significance) (Kuehl and Bergsagel, 2002).
Although enhancer NF1 sites were dispensable for tumor
induction by Akv1-99, this study unveiled a pivotal role of
these sequences in viral osteopetrosis induction. One may
speculate that NF1 site 1 is recognized by a protein complex
that represses proviral transcription, whereas NF1 site 2 is
bound by a complex that activates transcription in cell
type(s) that must be productively infected in the process of
osteopetrosis induction. It is even possible that the two sites
are recognized by the same complex, which could have a
down-regulatory function when bound to NF1 site 1 and an
up-regulatory function when bound to NF1 site 2. Transient
expression results indicated that NF1 sites are particularly
important for sustaining high viral gene expression levels in
osteoblastic cells, as compared to lymphoid cells. Hence,
NF1 motifs may determine Akv1-99 osteopetrosis induction
at least partly through regulation of viral protein expression
in bone forming cells, but we found no simple correlation
between viral enhancer strengths in the two osteoblastic cell
lines MC3T3 and KM1/K3 and the osteopetrosis induction
potential of the corresponding Akv1-99 viruses. Albeit
representing different stages of osteoblastic differentiation
these cell lines may not be representative of the host cell(s)
targeted by Akv1-99 during osteopetrosis induction. More-
over, NF1 proteins can regulate transcription by mecha-
nisms involving chromatin remodeling (Gronostajski,
2000), a regulatory level most likely not reflected in the
transient assays. Likewise, there was no linear correlation
between wild-type and NF1 site mutant SL3-3 transient
enhancer activities in these bone cell lines and viral bone
pathogenicity (Ethelberg et al., 1999).
The mechanism of viral osteopetrosis induction is still
unknown. It may develop independently of tumorigenesis
(Schmidt et al., 1999) or be caused by direct viral effects on
bone cells along with indirect effects mediated by virus-
induced (pre)leukemic cells in the bone marrow micro-
environment. Furthermore, the fact that MLV-induced
osteopetrosis seems only to develop in bones containing
bone marrow (Murray et al., 1991) may reflect the existence
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hematopoietic cells and bone marrow stromal cells. Finally,
the incidence of osteopetrosis in MLV-infected animals
might be affected by stochastic factors if a series of events is
needed to disrupt balanced bone remodeling. Each event
may not always occur or the events may not necessarily
appear in the required combination. In conclusion, this work
has provided novel mouse models of plasmacytoma devel-
opment, which are well-suited for future studies also
investigating potential pathophysiological effects on other
cell types than the target cells of oncogenic transformation,
in particular bone lesions as commonly seen in human
malignancies such as multiple myeloma.Materials and methods
Cell culture
MPC11 murine plasmacytoma B-cells, L691 murine T-
lymphoid cells, NIH 3T3 murine fibroblast cells and the
murine osteoblastic cell lines MC 3T3 (Sudo et al., 1983) and
KM1/K3 (Werenskiold et al., 1995) were grown as previ-
ously described (Ethelberg et al., 1997a, 1999). NALM6
human pre-B-cells (Hurwitz et al., 1979) were grown in
RPMI 1640 medium with Glutamax-1 (Gibco BRL, Invi-
trogen Corporation), supplemented with 10% newborn calf
serum, 100 U/ml penicillin and 100 Ag/ml streptomycin.
Plasmids
Chloramphenicol acetyl transferase (CAT) expression
vectors pAkv6cat and p1-99(wt)-cat have been described
previously (Lovmand et al., 1990), p1-99(m1)-cat is
identical to pM4 (Olsen et al., 1990), p1-99(m2)-cat was
provided by Dr. Jette Lovmand (Lovmand, 1996) and p1-
99(dmNF1)-cat was generated by exchanging an ApaI–
KpnI fragment between p1-99(m1)-cat and p1-99(m2)-cat.
The proviral clone of Akv1-99 harbors the complete viral
genome with one entire but permuted LTR (Lovmand et al.,
1998). Akv1-99 provirus plasmids with mutated NF1 site(s)
were made by substitution of a U3 containing PvuI–PvuI
fragment from the wild-type Akv1-99 proviral clone with an
equivalent PvuI–PvuI fragment from p1-99(m1)-cat, p1-
99(m2)-cat and p1-99(dmNF1)-cat, respectively.
Generation of viruses
Infectious virus particles were produced as previously
described. In short, concatemerized PstI–PstI fragments of
the proviral plasmid clones were transfected into NIH 3T3
cells (Ethelberg et al., 1997b; Lovmand et al., 1998), virus
production was monitored by RT assays (Hallberg et al.,
1991) and the LTR regions of proviruses were amplified
from virus producing NIH 3T3 cells by PCR and sequenced
(see below) to confirm the integrity of the mutations.Pathogenicity experiments and histopathological
examination
105 to 106 infectious virus particles, as measured by
infectious center assays (Schmidt et al., 1988), were injected
intraperitoneally into newborn inbred NMRI mice, which do
not harbor endogenous ecotropic MLVs (Leib-Mo¨sch et al.,
1986). Control mice from the same colony were mock
injected with complete medium. The mice were checked for
tumor development 5 days a week and sacrificed when they
showed signs of illness. Tumor development was diagnosed
on the basis of grossly enlarged lymphatic organs after
having reached the size described earlier, which is compat-
ible with lymphoma (Schmidt et al., 1984). Histological
examination of hematoxylin and eosin (H&E)-stained
sections from formalin-fixed and paraffin-embedded lym-
phoid organs was carried out for representative animals of
each group. Tumors were classified according to the
Bethesda proposals for classification of lymphoid neo-
plasms in mice (Morse et al., 2002). Immunohistochemistry
was performed on an automated immunostainer (Ventana
Medical System, Inc.; Tucson, AZ), according to the
protocol provided by the company. The antibody panel
used included polyclonal anti-CD3, anti-CD79a and anti-
TdT (Dako; Denmark). Osteopetrosis was diagnosed by X-
ray analysis. Positive cases were determined by a thickening
of bone trabecules and of the cortex together with a loss of
the spongious structure in the vertebrae and/or a loss of the
marrow cavity in other bones. Particular attention was put to
the primary sites of osteopetrosis, including the iliac crest,
the lower part of the lumbar vertebral column, ends of the
ribs, the distal femur and the proximal tibia. The analyses
were based on previous studies, which have shown in detail
that osteopetrosis is readily detected by X-ray (Ethelberg et
al., 1999; Murray et al., 1991; Schmidt et al., 1999).
Statistical calculations were carried out using the two-tailed
Fisher’s exact test.
Southern blotting analyses
Genomic DNA was extracted from frozen tumor tissues
using the DNeasy Tissue Kit (Qiagen). Southern blotting
and hybridizations with 32P random priming labeled probes
were performed as earlier (Ethelberg et al., 1997b). Hybrid-
ization probes used with HindIII-digested gDNA included
immunoglobulin kappa light chain (Ign) and T-cell receptor
h gene-specific probes TCRh-J1 and TCRh-J2. Further-
more, tumor DNAs were analyzed with an Ig heavy chain
specific probe (termed IgH-J11) after EcoRI digestion. All
probes were as previously described (Lovmand et al., 1998).
Transfections and reporter assays
MPC11, NALM6 and L691 were transfected by the
DEAE-dextran method (Ethelberg et al., 1997a), while NIH
3T3, MC 3T3 and KM1/K3 cells were transfected by
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1997a). For each transfection, 4 Ag (MPC11 and L691) or 3
Ag (NALM6, NIH 3T3, MC 3T3 and KM1/K3) CAT
expression vector was used together with 1.0 Ag (MC 3T3
and KM1/K3), 1.5 Ag (L691 and NIH 3T3) or 2.0 Ag
(MPC11 and NALM6) of pRSV-luc (Promega) internal
control plasmid to correct for variable transfection efficien-
cies. PUC19 carrier DNA was added to a total of 15 Ag
(L691, NIH 3T3, MC 3T3 and KM1/K3), 10 Ag (MPC11) or
8 Ag (NALM6) of DNA pr. transfection. All transfections
were done in duplicate and repeated three to eleven times.
CAT and luciferase assays were performed as described
earlier (Ethelberg et al., 1997a).
PCR and DNA sequencing analysis
Provirus LTR sequences were amplified from gDNA of
NIH 3T3 virus-producing cell lines and mouse tumor tissues
using primers 440 (5V-TTCATAAGGCTTAGCCAGC-
TAACTGCAG-3V; nucleotide positions 14 to 41 of the
Akv1-99 LTR) and 2620 (5V-biotin-GAATTCGATATC-
GATCCCCGGTCATCTGGG-3V; positions 278 to 261 of
the Akv1-99 LTR, with a 12-bp linker added for other
purposes (underlined)). In all cases, the PCR gave rise to a
single product of the expected size (277-bp). After
purification, either on streptavidin-coated magnetic beads
(Dynabead M280-streptavidin; Dynal AS, Oslo, Norway) or
by using the GFXTM PCR DNA and Gel Band Purification
Kit (Amersham Pharmacia Biotech), the amplification
products were sequenced on both strands using primers
440 and 2620, as described previously (Lovmand et al.,
1998; SØrensen et al., 1993).Acknowledgments
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